122 related articles for article (PubMed ID: 28746253)
1. A Case of Everolimus-Induced Eyelid Edema.
Schear MJ; Rodgers R
Ophthalmic Plast Reconstr Surg; 2018; 34(1):e21-e22. PubMed ID: 28746253
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressant-Related Lower Eyelid Edema in Transplant Patients.
Logan SA; Thyparampil PJ; Yen MT
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S58-S60. PubMed ID: 26730861
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus-associated eyelid edema in kidney transplant recipients.
Mohaupt MG; Vogt B; Frey FJ
Transplantation; 2001 Jul; 72(1):162-4. PubMed ID: 11468553
[TBL] [Abstract][Full Text] [Related]
4. [Edema of the eyelids caused by sirolimus in renal transplant recipients].
Schmutz JL; Barbaud A; Trechot P
Ann Dermatol Venereol; 2003 Jan; 130(1 Pt 1):83. PubMed ID: 12605170
[No Abstract] [Full Text] [Related]
5. Fatal acute pulmonary injury associated with everolimus.
Depuydt P; Nollet J; Benoit D; Praet M; Caes F
Ann Pharmacother; 2012 Mar; 46(3):e7. PubMed ID: 22333263
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow edema associated with everolimus.
McDevitt RL; Quinlan C; Hersberger K; Sahai V
Am J Health Syst Pharm; 2018 Jan; 75(1):e23-e27. PubMed ID: 29273609
[TBL] [Abstract][Full Text] [Related]
8. Ointment Granulomas Following Sutureless Transconjunctival Blepharoplasty: Diagnosis and Management.
Belinsky I; Patel P; Charles NC; Lisman RD
Ophthalmic Plast Reconstr Surg; 2015; 31(4):282-6. PubMed ID: 25216203
[TBL] [Abstract][Full Text] [Related]
9. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
11. A rare case of everolimus-induced pulmonary alveolar proteinosis.
Darley DR; Malouf MA; Glanville AR
J Heart Lung Transplant; 2016 Jan; 35(1):147-148. PubMed ID: 26525403
[No Abstract] [Full Text] [Related]
12. Everolimus-associated stomatitis in a patient who had renal transplant.
Ji YD; Aboalela A; Villa A
BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27797804
[TBL] [Abstract][Full Text] [Related]
13. Upper-eyelid wick syndrome: association of upper-eyelid dermatochalasis and tearing.
Avisar I; Norris JH; Selva D; Malhotra R
Arch Ophthalmol; 2012 Aug; 130(8):1007-12. PubMed ID: 22893070
[TBL] [Abstract][Full Text] [Related]
14. Everolimus: a guide to its use in liver transplantation.
Keating GM; Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
[TBL] [Abstract][Full Text] [Related]
15. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
16. Chronic eyelid swelling as an initial manifestation of myeloma-associated amyloidosis.
Chee E; Kim YD; Lee JH; Woo KI
Ophthalmic Plast Reconstr Surg; 2013; 29(1):e12-4. PubMed ID: 22955341
[TBL] [Abstract][Full Text] [Related]
17. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
18. Dermal filler-associated malar edema: Treatment of a persistent adverse effect.
Iverson SM; Patel RM
Orbit; 2017 Dec; 36(6):473-475. PubMed ID: 28837381
[TBL] [Abstract][Full Text] [Related]
19. Research and innovation in the development of everolimus for oncology.
Lebwohl D; Thomas G; Lane HA; O'Reilly T; Escudier B; Yao JC; Pavel M; Franz D; Berg W; Baladi JF; Stewart J; Motzer RJ
Expert Opin Drug Discov; 2011 Mar; 6(3):323-38. PubMed ID: 22647206
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex.
Kilincaslan A; Kok BE; Tekturk P; Yalcinkaya C; Ozkara C; Yapici Z
J Child Adolesc Psychopharmacol; 2017 May; 27(4):383-388. PubMed ID: 27797585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
